CytomX Therapeutics (United States)

Recent papers from CytomX Therapeutics (United States)

1. Spatial T lymphocyte infiltration into the primary melanoma tumor associates with survivalMelanoma Research · 2026
2. 12520 Preliminary Findings From An Ongoing Open-label Phase 2 Study Demonstrate That The Calcilytic Encaleret Can Improve The Relationship Between Blood And Urinary Calcium In Individuals With Post-surgical HypoparathyroidismJournal of the Endocrine Society · 2024
3. Virtual clinical trials via a QSP immuno-oncology model to simulate the response to a conditionally activated PD-L1 targeting antibody in NSCLCJournal of Pharmacokinetics and Pharmacodynamics · 2024
4. Eliciting the antitumor immune response with a conditionally activated PD‐L1 targeting antibody analyzed with a quantitative systems pharmacology modelCPT Pharmacometrics & Systems Pharmacology · 2023
5. The Role of Cysteine Protease Cathepsins B, H, C, and X/Z in Neurodegenerative Diseases and CancerInternational Journal of Molecular Sciences · 2023
6. SAT231 Next-generation Sequencing For Detection Of Underlying Genetic Causes Of Nonsurgical Hypoparathyroidism: Preliminary Results From A Sponsored Testing ProgramJournal of the Endocrine Society · 2023
7. The Role of Cysteine Peptidases Cathepsins B, H, C, and X/Z in Neurodegeneration and Cancer2023
8. A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited ToxicityCancer Research · 2022
9. Theranostic Applications of an Ultra-Sensitive T1 and T2 Magnetic Resonance Contrast Agent Based on Cobalt Ferrite Spinel NanoparticlesCancers · 2022
10. Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateMolecular Cancer Therapeutics · 2022
11. Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II TrialClinical Cancer Research · 2022
12. Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 AgentsCancer Immunology Research · 2021
13. Novel Ex Vivo Zymography Approach for Assessment of Protease Activity in Tissues with Activatable AntibodiesPharmaceutics · 2021
14. First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 ProbodyClinical Cancer Research · 2021
15. CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding studyJournal for ImmunoTherapy of Cancer · 2021
16. Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeuticProceedings of the National Academy of Sciences · 2021
17. Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor MalignanciesClinical Cancer Research · 2021
18. Autosomal Dominant Hypocalcemia Type 1: A Systematic ReviewJournal of Bone and Mineral Research · 2020
19. A Pilot Screen of a Novel Peptide Hormone Library Identified Candidate GPR83 LigandsSLAS DISCOVERY · 2020
20. Monitoring protease activity in biological tissues using antibody prodrugs as sensing probesScientific Reports · 2020